1988
DOI: 10.1016/s0190-9622(88)70022-5
|View full text |Cite
|
Sign up to set email alerts
|

History, pharmacokinetics, and pharmacology of acyclovir

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
31
0
1

Year Published

1996
1996
2017
2017

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 65 publications
(34 citation statements)
references
References 13 publications
0
31
0
1
Order By: Relevance
“…Most current cases of HSE are left with relatively circumscribed unilateral lesions (e.g., Tranel et al, 2000). Much of this reduced brain damage can be attributed to the introduction of acyclovir, a potent antiviral medication (King, 1988). Unfortunately for Roger, acyclovir's efficacy was not discovered until the mid-1980's, a few years after the onset of his encephalitic attack (Kennedy, 1988; Skoldenberg et al, 1984; Whitley et al, 1986).…”
Section: Discussionmentioning
confidence: 99%
“…Most current cases of HSE are left with relatively circumscribed unilateral lesions (e.g., Tranel et al, 2000). Much of this reduced brain damage can be attributed to the introduction of acyclovir, a potent antiviral medication (King, 1988). Unfortunately for Roger, acyclovir's efficacy was not discovered until the mid-1980's, a few years after the onset of his encephalitic attack (Kennedy, 1988; Skoldenberg et al, 1984; Whitley et al, 1986).…”
Section: Discussionmentioning
confidence: 99%
“…Treatment of herpesvirus infections primarily relies on nucleoside analog inhibitors of the viral DNA polymerase, including acyclovir (ACV), penciclovir, ganciclovir, valaciclovir, valganciclovir, brivudine, and famciclovir (10,11). Several newer agents are undergoing clinical development (11,12), but none of them can fully suppress herpesvirus infections (12).…”
mentioning
confidence: 99%
“…Acyclovir has been the standard in treating herpes simplex virus (HSV) 1 and 2 infections since 1982 . This drug is a nucleoside analogue, activated following conversion to acyclovir monophosphate and ultimately acyclovir triphosphate, via virus‐specific thymidine kinase and various cellular enzymes, respectively.…”
Section: Discussionmentioning
confidence: 99%
“…The final product prevents DNA replication by binding to viral DNA polymerase—terminating viral DNA production, effectively abating flares . Acyclovir pharmacodynamics display 15%–30% oral absorption, primary excretion through the urine (62%–90%), a volume of distribution of 0.8 L/kg in adults, and a half‐life of 20 hours in ESRD patients, as compared to 3–5 hours in adults with normal renal function . This medication is water‐soluble and has a low‐protein binding capacity of 15% .…”
Section: Discussionmentioning
confidence: 99%